<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395200</url>
  </required_header>
  <id_info>
    <org_study_id>MRCRG44871</org_study_id>
    <secondary_id>REC Reference: 07/Q0108/104</secondary_id>
    <nct_id>NCT00395200</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)</brief_title>
  <acronym>MSCIMS</acronym>
  <official_title>Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Intravenous administration of bone marrow-derived autologous adult human
      mesenchymal stem cells is a safe novel therapeutic approach for patients with multiple
      sclerosis.

      Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) is a phase I/IIA trial designed to
      establish the safety of intravenous administration of bone marrow-derived autologous adult
      human mesenchymal stem cells to patients with multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disease under investigation: Multiple Sclerosis

      Phase: I/IIA

      Number of patients: 10

      Design: 18 month cross over, single treatment at 6 months

      Intervention: Administration of bone marrow-derived autologous mesenchymal stem cells

      Route of administration: Intravenous

      Dose: Up to 2,000,000 Mesenchymal Stem Cells per kilogram

      Source of patients: Referrals accepted from Neurologists in East Anglia and North London, UK

      Referral Criteria: (all 3 required)

        1. Clinically definite multiple sclerosis

        2. Expanded Kurtzke Disability Status Score 2.0 - 6.5 (inclusive)

        3. Evidence of optic nerve damage by

             -  history of optic neuritis, or

             -  relative afferent pupillary defect, or

             -  optic atrophy on fundoscopy, or

             -  abnormal visual evoked potential from either or both eyes suggestive of
                demyelination

      Primary Objective: Establish the safety of intravenously administered bone marrow-derived
      autologous mesenchymal stem cells at a dose of up to 2,000,000 cells/kg over 12 months by
      monitoring adverse reactions.

      Secondary Objectives: Explore the efficacy of intravenously administered bone marrow-derived
      autologous mesenchymal stem cells at a dose of up to 2,000,000 cells/kg over 12 months on
      visual function by clinical, neurophysiological, and imaging assessments.

      Outcome Measures:

        1. Primary

             -  Adverse events

        2. Secondary

             -  Visual function (acuity and colour)

             -  Visual evoked potential latency

             -  Optic nerve Magnetisation Transfer Ratio

             -  Retinal nerve fibre layer thickness (by optical coherence tomography)

             -  Brain lesion Magnetisation Transfer Ratio

             -  MRI brain T1 hypointensity load

             -  T cell response suppression

        3. Tertiary

             -  Multiple Sclerosis Functional Composite Score

             -  Expanded Kurtzke Disability Status Score
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0,1,2,3,4,12 and 52 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual function (acuity and colour)</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual evoked potential latency</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optic nerve Magnetisation Transfer Ratio</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fibre layer thickness (by optical coherence tomography)</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain lesion Magnetisation Transfer Ratio</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI brain T1 hypointensity load</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite Score</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Kurtzke Disability Status Score</measure>
    <time_frame>12 and 52 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MSC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MSC Treatment</intervention_name>
    <description>Intravenous administration of up to 2x10^6 autologous MSCs per kg</description>
    <arm_group_label>MSC Treatment</arm_group_label>
    <other_name>Mesenchymal Stem Cells</other_name>
    <other_name>Multipotent Mesenchymal Stem Cells</other_name>
    <other_name>Multipotent Mesenchymal Stromal Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically definite multiple sclerosis

          -  Expanded Kurtzke Disability Status Score 2.0 - 6.5 (inclusive)

          -  Evidence of optic nerve damage by:

          -  history of optic neuritis, or

          -  relative afferent pupillary defect, or

          -  optic atrophy on fundoscopy, or

          -  abnormal visual evoked potential from either or both eyes suggestive of demyelination

          -  Prolonged visual evoked potential P100 latency with preserved waveform

          -  T2 lesion on MRI optic nerve

          -  Retinal nerve fibre layer thickness on optical coherence tomography &gt; 40 microns

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Age &gt; 65 years

          -  Patient lacks capacity to give informed consent

          -  Presence of a severe bleeding disorder

          -  Planning a pregnancy during the trial period

          -  Current MS disease modifying therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siddharthan Chandran, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cambridge Dept of Clinical Neurosciences</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Institute of Neurology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www-neurosciences.medschl.cam.ac.uk</url>
    <description>University of Cambridge Dept. of Clinical Neurosciences</description>
  </link>
  <link>
    <url>http://www.ion.ucl.ac.uk</url>
    <description>UCL Institute of Neurology</description>
  </link>
  <link>
    <url>http://www.trialsjournal.com/content/12/1/62/abstract</url>
    <description>Study protocol and baseline characteristics of the cohort</description>
  </link>
  <reference>
    <citation>Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011 Mar 2;12:62. doi: 10.1186/1745-6215-12-62.</citation>
    <PMID>21366911</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <last_update_submitted>October 22, 2011</last_update_submitted>
  <last_update_submitted_qc>October 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Peter Connick</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Safety</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Multipotent Mesenchymal Stromal Cells</keyword>
  <keyword>Optic Neuritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

